4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01640951 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

675

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Chronic Plaque-Type Psoriasis

Interventions

DRUG: AIN457 150 mg
DRUG: AIN457 300 mg
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals